Skip to main content
. 2022 Apr 6;17(4):e0266478. doi: 10.1371/journal.pone.0266478

Fig 2. Dynamics of the ubiquitin-modified proteome in AML cells after VCP inhibition.

Fig 2

(A) SILAC ratio distribution of all quantified ubiquitylation sites in MV4-11 and THP-1 cells. (B) Scatter plot showing SILAC ratios of quantified ubiquitylation sites in MV4-11 and THP-1 cells after treatment with the VCP inhibitor CB-5083.